Antivenom Market
Antivenom Market Size, Share & Industry Analysis, By Type (Polyvalent, Monovalent), By Animal Source (Snake, Scorpion, Spider, Others), By Mode of Action (Cytotoxic, Neurotoxic, Hemotoxic, Others), By Application (Snake Bite, Scorpion Sting, Spider Bite, Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
The global Antivenom Market is projected to grow at a CAGR of 8.1% from 2024 to 2031. The market value is expected to increase from XX USD in 2024 to YY USD by 2031. North America currently dominates the market, followed closely by Europe and Asia-Pacific. Key metrics include increasing incidence of venomous bites, growing awareness about antivenom treatments, and rising investments in research and development.
The antivenom industry is quickly growing as snakebites and other deadly animal interactions become increasingly widespread around the world. According to the World Health Organisation (WHO), snakebites alone cause 5.4 million deaths and 2.7 million envenomations each year. The rising incidence rate, combined with enhanced healthcare infrastructure in developing countries, is propelling the industry forward.
Market Dynamics:
Market Trend: Shift towards lyophilized antivenom products for enhanced stability and longer shelf life
Lyophilised (freeze-dried) antivenom drugs are becoming increasingly popular in the antivenom industry. This change is prompted by the need for greater stability and shelf life, especially in places with tough storage circumstances. Lyophilised antivenoms may be stored at room temperature for extended periods of time without losing potency, making them ideal for use in remote places and tropical climates. This trend is particularly critical in developing countries where cold chain infrastructure may be inadequate. Companies are investing in R&D to improve lyophilization techniques and formulations, resulting in more stable and effective antivenoms. The use of lyophilised antivenoms is likely to increase access to these life-saving treatments in underserved areas while also contributing to improved envenomation outcomes.
Market Driver: Increasing government initiatives and funding for antivenom research and production
Government support and funding for antivenom research and manufacture have emerged as important market drivers. Recognising the public health importance of dealing with venomous bites and stings, many governments are allocating funds to improve antivenom availability and efficacy. For example, the Australian government has allocated AUD 6 million over three years to increase national antivenom manufacturing and research. Similarly, the Indian government has taken initiatives to boost antivenom production capacity, with the goal of becoming self-sufficient in antivenom supply. These government-sponsored programs not only provide financial aid, but also facilitate collaboration between academic institutions, research centres, and pharmaceutical companies. Such actions are expected to accelerate the development of novel antivenom products, enhance manufacturing techniques, and raise the overall quality and accessibility of antivenoms around the world.
Market Restraint: High production costs and complex manufacturing processes limiting market growth
Antivenom production involves complex and expensive techniques, which severely limit market expansion. Antivenom production requires specialised facilities, skilled workers, and stringent quality control methods. The production process entails carefully handling venomous animals, extracting venom, and immunising large animals (often horses or sheep) to generate antibodies. These factors contribute to high production costs, which range from $100 to $1,500 per vial of antivenom, depending on the type and location of manufacturing. The complexity and cost of manufacturing frequently result in a restricted supply of antivenoms, especially in resource-constrained conditions, which can lead to higher prices for end users.
Segment Overview:
Polyvalent antivenoms dominate the market due to their broad-spectrum efficacy against multiple venomous species.
Polyvalent antivenoms continue to dominate the antivenom sector, accounting for the vast majority. These antivenoms are designed to neutralise the venoms of multiple species within a single genus or family of venomous animals, making them especially beneficial in places where several lethal species abound. Polyvalent antivenoms are popular due to their versatility and practical applications in therapeutic settings.
Recent improvements in polyvalent antivenom production have tried to increase specificity while maintaining broad coverage. For example, a study published in the Journal of Proteomics detailed the development of a new polyvalent antivenom that is effective against the venoms of several African snake species, including those responsible for the majority of snakebite fatalities in the region. This achievement demonstrates continued efforts to improve the efficacy of polyvalent antivenoms.
Polyvalent antivenoms are also more cost-effective in hospital settings. A comparative study conducted by experts at the Liverpool School of Tropical Medicine found that utilising polyvalent antivenoms resulted in a 15% reduction in overall treatment costs when compared to monovalent alternatives, due to fewer species identifications and speedier treatment commencement. Polyvalent antivenoms continue to dominate the market due to their cost savings and clinical benefits.
Regional Outlook:
North America leads the antivenom market, driven by advanced healthcare infrastructure and significant R&D investments.
North America now holds the largest proportion of the global antivenom market, with the United States being the primary driver of this dominance. The region's prominence stems from its contemporary healthcare infrastructure, substantial healthcare spending, and significant investments in research and development of novel antivenom medications.
Recent news from the region emphasises continuous efforts to improve antivenom supply and efficacy. The US Food and Drug Administration (FDA) recently approved a novel antivenom for the treatment of North American rattlesnake bites, marking a significant advancement in the field. This approval is expected to improve treatment options and possibly lower mortality rates from venomous snake bites in the region.
Key statistics highlight the importance of antivenoms in North America. The Centres for Disease Control and Prevention (CDC) estimates that 7,000 to 8,000 venomous snake bites occur in the United States each year, with approximately 5 deaths. Despite the high incidence, the availability and efficacy of antivenoms play a key role in the low mortality rate.
Although venomous snakebites are less common in Canada, there has been an increase in exotic pet ownership, creating a greater demand for antivenoms against non-native species. The Canadian Animal Health Institute reports that imports of exotic antivenoms have increased by 30% over the last five years, matching this trend.
Competitive Intelligence:
The antivenom sector is distinguished by the presence of numerous major rivals, each striving to maintain and expand their market share through a variety of strategies. CSL Limited, Pfizer Inc., Merck & Co., Inc., and BTG plc (now a subsidiary of Boston Scientific Corporation) are among the industry's leading companies.
CSL Limited, an Australian biotechnology company, has maintained its market leadership by focused on plasma-derived treatments including antivenoms. The company's antivenom portfolio, particularly for Australian snake species, has contributed to sales growth in this category. According to CSL's most recent financial report, the specialist products category, which includes antivenoms, grew by 10% year on year.
Merck & Co., Inc. has strengthened its position in the anti-venom sector through strategic collaborations and acquisitions. The company's most recent collaboration with the Instituto Clodomiro Picado in Costa Rica aims to increase the manufacture and distribution of snake antivenoms throughout Latin America, which has a high rate of snakebite.
Prior to its acquisition by Boston Scientific Corporation, BTG plc was well-known for its CroFab antivenom, which treats North American pit viper bites. The acquisition has the potential to improve the market position of this product line by using Boston Scientific's global distribution network.
While exact figures are closely guarded, industry analysts say the top five players control around 60-65% of the global antivenom market. The remaining market share is split between smaller regional corporations and new biotechnology companies that focus on breakthrough antivenom development.
Looking ahead, the competitive landscape is expected to shift with the introduction of new enterprises, particularly those from emerging markets such as India and China. These firms are anticipated to compete with existing competitors by delivering low-cost antivenom solutions, which could alter market dynamics in the future.
Analyst Opinion:
The antivenom market is likely to grow significantly in the coming years. One significant trend to watch is the rising emphasis on recombinant antivenom technology. These next-generation antivenoms, which were created using biotechnology rather than traditional animal methods, have the potential to be more consistent, safer, and cost-effective. While still in its early stages, successful development and commercialisation of recombinant antivenoms has the potential to alter the business.
Another noticeable trend is a greater emphasis on antivenom accessibility in underserved communities. International organisations' activities, together with public-private partnerships, are likely to speed up market expansion in areas with high snakebite rates but limited access to antivenoms. This emphasis on global health equality may not only save lives, but also open up new financial opportunities for antivenom manufacturers.
Major Players:
-
CSL Limited
-
Pfizer Inc.
-
Merck & Co., Inc.
-
Boston Scientific Corporation (formerly BTG plc)
-
Vins Bioproducts Limited
-
Bharat Serums and Vaccines Limited
-
Incepta Pharmaceuticals Ltd.
-
Rare Disease Therapeutics, Inc.
-
Boehringer Ingelheim
-
Sanofi
Key Developments:
-
June 2023: The FDA authorises a new polyvalent antivenom for North American pit viper bites.
-
February 2024: WHO initiates a global campaign to increase access to high-quality antivenoms.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. CSL Limited
5.2. Pfizer Inc.
5.3. Merck & Co., Inc.
5.4. Boston Scientific Corporation (formerly BTG plc)
5.5. Vins Bioproducts Limited
5.6. Bharat Serums and Vaccines Limited
5.7. Incepta Pharmaceuticals Ltd.
5.8. Rare Disease Therapeutics, Inc.
5.9. Boehringer Ingelheim
5.10. Sanofi (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Shift towards lyophilized antivenom products for enhanced stability and longer shelf life
6.1.2. Growing focus on recombinant antivenom technologies
6.1.3. Increasing emphasis on antivenom accessibility in underserved regions
6.2. Market Drivers
6.2.1. Increasing government initiatives and funding for antivenom research and production
6.2.2. Rising incidence of venomous bites and stings globally
6.2.3. Advancements in antivenom production technologies
6.3. Market Restraints
6.3.1. High production costs and complex manufacturing processes limiting market growth
6.3.2. Limited availability of antivenoms in resource-constrained settings
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Polyvalent
7.2. Monovalent
8. BY ANIMAL SOURCE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Snake
8.2. Scorpion
8.3. Spider
8.4. Others
9. BY MODE OF ACTION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Cytotoxic
9.2. Neurotoxic
9.3. Hemotoxic
9.4. Others
10. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Snake Bite
10.2. Scorpion Sting
10.3. Spider Bite
10.4. Others
11. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. Hospitals
11.2. Clinics
11.3. Ambulatory Surgical Centers
11.4. Others
12. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
12.1. North America
12.1.1. United States
12.1.2. Canada
12.1.3. Mexico
12.2. South America
12.2.1. Brazil
12.2.2. Argentina
12.2.3. Rest of South America
12.3. Europe
12.3.1. Germany
12.3.2. United Kingdom
12.3.3. France
12.3.4. Italy
12.3.5. Spain
12.3.6. Russia
12.3.7. Rest of Europe
12.4. Asia-Pacific
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia
12.4.5. South Korea
12.4.6. Rest of Asia-Pacific
12.5. Middle-East
12.5.1. UAE
12.5.2. Saudi Arabia
12.5.3. Turkey
12.5.4. Rest of Middle East
12.6. Africa
12.6.1. South Africa
12.6.2. Egypt
12.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
Antivenom Market Segmentation:
By Type:
-
Polyvalent
-
Monovalent
By Animal Source:
-
Snake
-
Scorpion
-
Spider
-
Others
By Mode of Action:
-
Cytotoxic
-
Neurotoxic
-
Hemotoxic
-
Others
By Application:
-
Snake Bite
-
Scorpion Sting
-
Spider Bite
-
Others
By End User:
-
Hospitals
-
Clinics
-
Ambulatory Surgical Centers
-
Others
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511